Journal Article

DKFZ-2024-01971

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.

Leypoldt, L. B. ; Tichy, D.DKFZ* ; Besemer, B. ; Hanel, M. ; Raab, M. S. ; Mann, C. ; Munder, M. ; Reinhardt, H. C.DKFZ* ; Nogai, A. ; Gorner, M. ; Ko, Y.-D. ; Wit, M. d. ; Salwender, H. ; Scheid, C. ; Graeven, U. ; Peceny, R. ; Staib, P. ; Dieing, A. ; Einsele, H. ; Jauch, A. ; Hundemer, M. ; Zago, M. ; Pozek, E.DKFZ* ; Benner, A.DKFZ* ; Bokemeyer, C. ; Goldschmidt, H. ; Weisel, K. C.

2024
Future Medicine Ltd London

This record in other databases:

Please use a persistent id in citations: doi:10.1080/14796694.2024.2402639

Keyword(s): clinical trial ; high-risk ; isatuximab ; multiple myeloma (MM) ; plain language summary

Note: 2024 Dec;20(39):3193-3207

---

Contributing Institute(s):

1. C060 Biostatistik (C060)
2. DKTK Koordinierungsstelle Essen/Düsseldorf (ED01)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2024

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---